Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue SUPPL.1, 2013, Pages

  Ventrice, Pasquale ^a,b   Leporini, Christian ^a,b   Aloe, Jose Francisco ^c   Greco, Ettore ^d   Leuzzi, Giacomo ^a,b   Marrazzo, Giuseppina ^a,b   Scorcia, Giovanni ^a   Bruzzichesi, Donatella ^a   Nicola, Varano ^a   Scorcia, Vincenzo ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Policlinico Mater Domini   (Italy)

^c Azienda Sanitaria Locale 10   (Italy)

^d Giovanni Paolo II Hospital   (Italy)

Author keywords

Adverse drug reactions; aflibercept; age related macular degeneration; bevacizumab; choroidal neovascularization; ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ARTERIAL THROMBOEMBOLISM; ARTERY THROMBOSIS; BENIGN TUMOR; CATARACT; CENTRAL RETINA VEIN OCCLUSION; DIABETIC RETINOPATHY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; EYE DISEASE; EYE INFLAMMATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; INFLAMMATION; INTRAOCULAR PRESSURE ABNORMALITY; MALIGNANT NEOPLASTIC DISEASE; METASTATIC COLORECTAL CANCER; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; OFF LABEL DRUG USE; PSEUDOENDOPHTHALMITIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; REVIEW; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TRANSIENT ISCHEMIC ATTACK; UVEITIS; VEIN THROMBOSIS; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 84889592452     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.120947     Document Type: Review

References (38)

1. Pascolini D, Mariotti SP, Pokharel GP, Pararajasegaram R, Etya'ale D, Négrel AD, et al. 2002 global update of available data on visual impairment: A compilation of population-based prevalence studies. Ophthalmic Epidemiol 2004;11:67-115.
2. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann Med 2006;38:450-471.
3. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ 2003;326:485-8.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
6. Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-87.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
8. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): A dual regulator for angiogenesis. Angiogenesis 2006;9:225-30; discussion 231.
9. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
10. Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K, Inomata H. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997;235:159-67.
11. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2000;41:3158-64.
12. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: Six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-6.
13. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:311-8.
14. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
15. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
16. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113,no. 1695.e1-15
17. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
18. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
19. Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): Modelling cost effectiveness. Br J Ophthalmol 2007;91:1244-6.
20. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald E, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
21. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
22. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48.
23. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-93.
24. Heier JS, Brown DM, Chong V. VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
25. Heier JS, Boyer D, Nguyen QD, Marcus D, Roth DB, Yancopoulos G, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011;118:1098-106.
26. Wong LJ, Desai RU, Jain A, Feliciano D, Moshfeghi DM, Sanislo SR, et al. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 2008;28:1151-8.
27. Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457-62.
28. Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327-333.e1.
29. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9.
30. Hwang DJ, Kim YW, Woo SJ, Park KH. Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: Ranibizumab versus bevacizumab. J Korean Med Sci 2012;27:1580-5.
31. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: A comprehensive review. Retina 2004;24:676-98.
32. Sato T, Emi K, Ikeda T, Bando H, Sato S, Morita S, et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology 2010;117:512-6, 516.e1.
33. Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik M, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241-7.
34. Nguyen QD, Campochiaro PA, Shah SM, Browning DJ, Hudson HL, Sonkin PL, et al. Evaluation of very high-and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. J Ocul Pharmacol Ther 2012;28:581-8.
35. Chen E, Brown DM, Wong TP, Benz MS, Kegley E, Cox J, et al. Lucentis using Visudyne study: Determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. Clin Ophthalmol 2010;4:1073-9.
36. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): Results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-78.
37. Kovach JL, Schwartz SG, Flynn HW Jr, Scott IU. Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol 2012;2012:786-870.
38. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 2008;6:12.